News and publications
Publications
Below is a list of select publications co-authored by Deep Apple founders and/or scientists that describe the science underlying Deep Apple’s approach to drug discovery.
Docking for EP4R antagonists active against inflammatory pain
(Nature Communications, 06 December 2023)
Time-resolved cryo-EM of G protein activation by a GPCR
(bioRxiv preprint, 21 March 2023)
Insights into distinct signaling profiles of the µOR activated by diverse agonists
(Nature Chemical Biology, 21 November 2022)
Structure determination of inactive-state GPCRs with a universal nanobody
(Nature Structural & Molecular Biology, 17 November 2022)
Structure-based discovery of nonopioid analgesics acting through the α2A-adrenergic receptor
(Science, 30 September 2022)
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
(Nature, 28 September 2022)
Ultra-large library docking for discovering new chemotypes
(Nature, 06 February 2019)
Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases
SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PR Newswire/ – Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models
SAN FRANCISCO and NEW YORK, December 14, 2023/PR Newswire/ – Apple Tree Partners (ATP), a leader in life sciences venture capital, today announced $52 million in Series A funding for its portfolio company Deep Apple Therapeutics, created and incubated by ATP to rapidly discover novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries.